In contrast to conventional therapeutic targeting of cathepsins, our data demonstrate that inhibiting specifically the extracellular fraction of CTSD can be a valuable therapeutic strategy for NAFLD. The gene discussed is CTSS; the disease is metabolic dysfunction-associated steatotic liver disease.